Selected Active Clinical Trials Involving/Exploring the Glioma Microenvironment
| Trial ID . | Title . | Location . |
|---|---|---|
| NCT04781764 | The Study of Microglia/Macrophages Involved Dynamic Evolution of Glioma Microenvironment and the Function and Visualization of Targeted Molecules of Glioma | Hushan Hospital Fudan University, China |
| NCT04729959 | A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma | Peking University Third Hospital, China |
| NCT04461938 | Characterization of Metabolic Changes in Glioma Tumor Tissue Induced by Transient Fasting (ERGO3) | Goethe University, Germany |
| NCT04606316 | A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients with Surgically Accessible Glioblastoma | Dana-Farber Cancer Center, USA |
| NCT05053880 | A Phase 1b/2a Study of ACT001 and Anti-PD-1 in Patients with Surgically Accessible Recurrent Glioblastoma Multiforme | The University of Texas MD Anderson Cancer Center, USA |
| NCT03673787 | Ice-CAP: A Phase I Trial of Ipatasertib in Combination with Atezolizumab in Patients with Advanced Solid Tumours with PI3K Pathway Hyperactivation | Institute of Cancer Research, UK |
| NCT04656535 | A Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination with Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma | Yale University, USA |
| Trial ID . | Title . | Location . |
|---|---|---|
| NCT04781764 | The Study of Microglia/Macrophages Involved Dynamic Evolution of Glioma Microenvironment and the Function and Visualization of Targeted Molecules of Glioma | Hushan Hospital Fudan University, China |
| NCT04729959 | A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma | Peking University Third Hospital, China |
| NCT04461938 | Characterization of Metabolic Changes in Glioma Tumor Tissue Induced by Transient Fasting (ERGO3) | Goethe University, Germany |
| NCT04606316 | A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients with Surgically Accessible Glioblastoma | Dana-Farber Cancer Center, USA |
| NCT05053880 | A Phase 1b/2a Study of ACT001 and Anti-PD-1 in Patients with Surgically Accessible Recurrent Glioblastoma Multiforme | The University of Texas MD Anderson Cancer Center, USA |
| NCT03673787 | Ice-CAP: A Phase I Trial of Ipatasertib in Combination with Atezolizumab in Patients with Advanced Solid Tumours with PI3K Pathway Hyperactivation | Institute of Cancer Research, UK |
| NCT04656535 | A Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination with Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma | Yale University, USA |
Selected Active Clinical Trials Involving/Exploring the Glioma Microenvironment
| Trial ID . | Title . | Location . |
|---|---|---|
| NCT04781764 | The Study of Microglia/Macrophages Involved Dynamic Evolution of Glioma Microenvironment and the Function and Visualization of Targeted Molecules of Glioma | Hushan Hospital Fudan University, China |
| NCT04729959 | A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma | Peking University Third Hospital, China |
| NCT04461938 | Characterization of Metabolic Changes in Glioma Tumor Tissue Induced by Transient Fasting (ERGO3) | Goethe University, Germany |
| NCT04606316 | A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients with Surgically Accessible Glioblastoma | Dana-Farber Cancer Center, USA |
| NCT05053880 | A Phase 1b/2a Study of ACT001 and Anti-PD-1 in Patients with Surgically Accessible Recurrent Glioblastoma Multiforme | The University of Texas MD Anderson Cancer Center, USA |
| NCT03673787 | Ice-CAP: A Phase I Trial of Ipatasertib in Combination with Atezolizumab in Patients with Advanced Solid Tumours with PI3K Pathway Hyperactivation | Institute of Cancer Research, UK |
| NCT04656535 | A Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination with Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma | Yale University, USA |
| Trial ID . | Title . | Location . |
|---|---|---|
| NCT04781764 | The Study of Microglia/Macrophages Involved Dynamic Evolution of Glioma Microenvironment and the Function and Visualization of Targeted Molecules of Glioma | Hushan Hospital Fudan University, China |
| NCT04729959 | A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma | Peking University Third Hospital, China |
| NCT04461938 | Characterization of Metabolic Changes in Glioma Tumor Tissue Induced by Transient Fasting (ERGO3) | Goethe University, Germany |
| NCT04606316 | A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients with Surgically Accessible Glioblastoma | Dana-Farber Cancer Center, USA |
| NCT05053880 | A Phase 1b/2a Study of ACT001 and Anti-PD-1 in Patients with Surgically Accessible Recurrent Glioblastoma Multiforme | The University of Texas MD Anderson Cancer Center, USA |
| NCT03673787 | Ice-CAP: A Phase I Trial of Ipatasertib in Combination with Atezolizumab in Patients with Advanced Solid Tumours with PI3K Pathway Hyperactivation | Institute of Cancer Research, UK |
| NCT04656535 | A Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination with Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma | Yale University, USA |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
